4
ALL4
Fosun Kite BiotechnologyYear
4
ALL1
20231
20221
20211
2020DEALS // DEV.
4
ALL4
DevelopmentsCountry
4
ALL4
CHINA4
ALL4
InapplicableTherapeutic Area
4
ALL4
OncologyStudy Phase
4
ALL4
Approved FDFDeal Type
4
ALL4
InapplicableProduct Type
4
ALL4
Cell and Gene therapyDosage Form
4
ALL3
Intravenous Infusion1
Intravenous InjectionLead Product
4
ALL4
Axicabtagene CiloleucelTarget
4
ALL4
CD19Lead Product(s) : Axicabtagene Ciloleucel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Yikaida CAR-T Cell Therapy Approved as a Second-line Therapy for New Indication
Details : YIKAIDA (axicabtagene ciloleucel injection) is an autologous CD19-targeted CAR T-cell therapy that was authorized to be locally produced in China using Yescarta® technology from Kite Pharma, Inc.
Product Name : Yikaida
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 18, 2023
Lead Product(s) : Axicabtagene Ciloleucel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Axicabtagene Ciloleucel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : YIKAIDA (axicabtagene ciloleucel injection) is an autologous CD19-targeted CAR T-cell therapy that was authorized to be locally produced in China using Yescarta® technology from Kite Pharma, Inc.
Product Name : Yikaida
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : Axicabtagene Ciloleucel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Axicabtagene Ciloleucel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China's First CAR-T Cell Therapy Approved-Fosun Kite Axicabtagene Ciloleucel (FKC876)
Details :
Product Name : Yikaida
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 24, 2021
Lead Product(s) : Axicabtagene Ciloleucel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Axicabtagene Ciloleucel,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Yikaida
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 24, 2020
Lead Product(s) : Axicabtagene Ciloleucel,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable